Baillie Gifford & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $989M | Sell |
|
|||||
|
2025
Q1 | $988M | Sell |
|
|||||
|
2024
Q4 | $951M | Sell |
|
|||||
|
2024
Q3 | $1.34B | Sell |
|
|||||
|
2024
Q2 | $1.47B | Sell |
|
|||||
|
2024
Q1 | $990M | Sell |
|
|||||
|
2023
Q4 | $1.33B | Sell |
|
|||||
|
2023
Q3 | $1.45B | Sell |
|
|||||
|
2023
Q2 | $1.59B | Sell |
|
|||||
|
2023
Q1 | $1.73B | Sell |
|
|||||
|
2022
Q4 | $2.24B | Sell |
|
|||||
|
2022
Q3 | $1.9B | Sell |
|
|||||
|
2022
Q2 | $1.45B | Sell |
|
|||||
|
2022
Q1 | $1.66B | Sell |
|
|||||
|
2021
Q4 | $1.8B | Buy |
|
|||||
|
2021
Q3 | $1.97B | Buy |
|
|||||
|
2021
Q2 | $1.73B | Buy |
|
|||||
|
2021
Q1 | $1.42B | Buy |
|
|||||
|
2020
Q4 | $1.19B | Buy |
|
|||||
|
2020
Q3 | $1.29B | Buy |
|
|||||
|
2020
Q2 | $1.28B | Buy |
|
|||||
|
2020
Q1 | $916M | Buy |
|
|||||
|
2019
Q4 | $943M | Sell |
|
|||||
|
2019
Q3 | $662M | Buy |
|
|||||
|
2019
Q2 | $451M | Buy |
|
|||||
|
2019
Q1 | $531M | Buy |
|
|||||
|
2018
Q4 | $346M | Buy |
|
|||||
|
2018
Q3 | $391M | Buy |
|
|||||
|
2018
Q2 | $417M | Buy |
|
|||||
|
2018
Q1 | $457M | Buy |
|
|||||
|
2017
Q4 | $459M | Buy |
|
|||||
|
2017
Q3 | $400M | Sell |
|
|||||
|
2017
Q2 | $274M | Buy |
|
|||||
|
2017
Q1 | $171M | Buy |
|
|||||
|
2016
Q4 | $124M | Sell |
|
|||||
|
2016
Q3 | $228M | Sell |
|
|||||
|
2016
Q2 | $188M | Buy |
|
|||||
|
2016
Q1 | $212M | Buy |
|
|||||
|
2015
Q4 | $257M | Buy |
|
|||||
|
2015
Q3 | $57M | Sell |
|
|||||
|
2015
Q2 | $94.9M | Sell |
|
|||||
|
2015
Q1 | $107M | Sell |
|
|||||
|
2014
Q4 | $106M | Sell |
|
|||||
|
2014
Q3 | $93M | Hold |
|
|||||
|
2014
Q2 | $75.2M | Buy |
|
|||||
|
2014
Q1 | $72M | Buy |
|
|||||
|
2013
Q4 | $57.5M | Buy |
|
|||||
|
2013
Q3 | $48.2M | Sell |
|
|||||
|
2013
Q2 | $27.9M | Buy |
|